Dr. Leonardo Villacrés (Oncólogo clínico)

3 Amores en mi vida.... Dios.. mi familia y la oncologia clinica

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@Rutmercedes Pero si Merino es correista... Apoyó a Pabel para llegar a la Concejalía... Cual es la diferencia...

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@fmolestinae Esa no es la vuelta al Ecuador... Es un fin de semana normal...

Vayan al Parque.. Las ganas de joder al resto..

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@LaCapitalNews Felicitaciones a la Policía de NY solo hizo su trabajo..

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@plomoterap30 Promedio

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@PTarantinoMD Maybe it's a simple curve when you compare with crizotinib, we need a new curve between lorlatinib vs alectinib

[Jame Abraham, MD, FACP @jamecancerdoc]

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice https://t.co/OlPqUor0xf @JCOOP_ASCO @ASCO @OncoAlert one of the most common consults in General HemOnc Clinics

[Oncology Brothers @OncBrothers]

This is the treatment algorithm we have used to drive our 🗣️ with @lungoncdoc on targeted options in 1L for metastatic NSCLC!

✅ Zongertinib recently added
✅ Data around front line when you have multiple options
✅ Role of Re-testing

#lcsm #OncTwitter @OncoAlert @OncUpdates

[Dr Amol Akhade @SuyogCancer]

What's New data in breast cancer at ASCO 2026 ?
Check this out 🙂👇 @ASCO #ASCO26

[Yakup Ergün @dr_yakupergun]

Algorithm for Systemic Therapy in Early HR+/HER2- Breast Cancer

(Recommendations in gray areas reflect my own clinical judgment— eg. olaparib and CDK4/6 sequence)

[Dr Rishabh Jain @DrRishabhOnco]

Not all stage IC ovarian cancers need chemo.

This IJGC review supports selective de-escalation 👇 

🟢 Consider NO chemo
Low-grade serous
Grade 1 endometrioid
Expansile mucinous
Clear cell IC1

🔴 Chemo still needed
High-grade serous
Clear cell IC2/3
High-grade endometrioid
Infiltrative mucinous

🧠 Takeaway
Stage IC ≠ one disease
👉 Treat by histology + staging, not habit

🔖 Save this

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #GynOnc #OvarianCancer
@OncoAlert @myesmo @esmo_open @asco

[Dr. Leonardo Villacrés (Oncólogo clínico) @davidvillacrs]

@BNPeriodismo @quematucabeza Porque habla así?

[Dr Rishabh Jain @DrRishabhOnco]

🧬 Can we skip Oncotype DX… and still decide chemotherapy?

A Lancet Oncology AI study tackles this head-on in HR+ / HER2− early breast cancer by predicting recurrence score directly from H&E slides + clinicopath data.

Study backbone:
•🧪 Training/validation: TAILORx (n=8284)
•🌍 External validation: 6 cohorts (n=5497) 

Performance 📊
•🎯 High genomic risk (RS ≥26): AUC 0.898
•Risk split (TAILORx test):
•🟢 Low: 45.6%
•🟡 Intermediate: 42.4%
•🔴 High: 12.0% 

Where it gets clinically interesting 👇

👩‍🦰 Premenopausal
•🔴 AI high-risk → chemo benefit (HR 0.63)

👩 Postmenopausal
•🟢 AI low-risk → no chemo benefit (HR 0.94)
•⚠️ 31.3% clinically high-risk → reclassified as low AI risk (no chemo signal)

Why this matters 💡
•Bridges digital pathology → treatment decisions
•Potentially reduces dependence on costly genomic assays
•Especially relevant for resource-limited settings

But ⚠️
•Retrospective model
•Needs prospective validation before practice change

👉 Pathology slides might soon guide chemo decisions. Are we ready?

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #AIinOncology
@oncoalert

[MV Chandrakanth @ChandrakanthMv]

NORTHSTAR: Who really benefits from LCT?
Not everyone with EGFR NSCLC.
✔ No thoracic LN
✔ No pleural effusion
✔ Curative RT feasible
👉 It’s not oligometastasis… it’s oligobiology
#ELCC2026 #ESMO #MVOnco #LungCancer

[MV Chandrakanth @ChandrakanthMv]

NorthStar trial 🌟
Osimertinib + LCT vs osimertinib alone
PFS: 25.4 vs 17.0 mo
HR 0.60 (p=0.02)
Not just oligometastatic—benefit seen even beyond
👉 Target residual disease, delay resistance
#MVOnco #Oncology #LungCancer #EGFR

[MV Chandrakanth @ChandrakanthMv]

If you remember only one thing from BRCA biology, remember this👇
• BRCA1 → detects DNA damage
• BRCA2 → repairs DNA
• PARP → fixes small damage
Block PARP + lose BRCA2 → no repair left → cell dies
👉 That’s why PARP works best in BRCA2
#MVOnco #Oncology #MedOnc

[MV Chandrakanth @ChandrakanthMv]

WHO changed glioma classification forever
• Molecular first, not histology
• IDH defines biology
• Grade ≠ disease
• Grade 1 = only circumscribed
Simple way to remember 👇
#MVOnco #Glioma #NeuroOncology #MedEd #Oncology

[MV Chandrakanth @ChandrakanthMv]

INDIGO Trial 👇
• PFS: 27.7 vs 11.1 mo
• Delays RT/chemo (TTNI NR vs 17.8)
• Seizures ↓
• QoL preserved
👉 Best in early mIDH grade 2 glioma
👉 Hit IDH early or miss the window
#MVOnco #Glioma #NeuroOncology #Oncology

[MV Chandrakanth @ChandrakanthMv]

WHO 2021 changed glioma forever
Same histology ≠ same treatment
• IDH, 1p/19q, MGMT drive decisions
• From observation → RT → chemo → delay strategies
Think molecular → treat smarter 🧠
#MVOnco #NeuroOncology #Glioma

[MV Chandrakanth @ChandrakanthMv]

Adjuvant therapy in resected NSCLC — who benefits?
• Stage IA → No chemotherapy
• Stage IB → Consider if high-risk
• Stage II–IIIA → Standard
Cisplatin doublets improve OS (~5%).
Modern era: targeted therapy & immunotherapy.
#MVOnco #LungCancer #Oncology #MedOnc

[MV Chandrakanth @ChandrakanthMv]

Rectal cancer treatment is moving toward DE-ESCALATION.

• dMMR → Immunotherapy first
• Upper/Mid rectum → Radiation may be omitted
• Lower rectum → Organ preservation (OPRA watch-and-wait)

Biology + anatomy now guide therapy.

#MVOnco #RectalCancer #Oncology